I'm not sure if I can answer whether or not its a good buying opportunity. However, I'm thinking that there in a better position cash burn wise (looking at developments over the last 6 months instead of two years) having reduced this significantly over the past 2 quarters, plus they have rental income from the R & D facility and have significantly increased their R & D expenditure (of which they will receive a tax credit for).
I'm hoping they can now get cracking with the product pipeline. There is a growing market for these types of products (and the pet market is largely untapped in Australia).
Not sure about the vertical integration, I thought with the ease of access (lots of competition) and low prices for growing, AC8 would be better concentrating elsewhere.
- Forums
- ASX - By Stock
- AC8
- Whats Next
Whats Next, page-29
Featured News
Add AC8 (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Will Souter, CFO
Will Souter
CFO
Previous Video
Next Video
SPONSORED BY The Market Online